Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC ODT
B
iohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced a collaboration with Cove, a company providing specialized care and access to innovative treatments for migraine sufferers via telemedicine services in the United States.
The collaboration seeks to facilitate telemedicine evaluation for migraine sufferers while patients are increasingly looking to remote evaluations during this time of unprecedented decreased access to routine office visits.
The intent of this initiative is to further expand patients' access to migraine treatments, like NURTEC ODT, an orally disintegrating tablet recently approved for the acute treatment of migraine in adults. Using Cove, patients consult with independent healthcare providers and may be prescribed NURTEC ODT along with other migraine treatments which provides patients an important alternative to in-office doctor visits. NURTEC ODT is the first calcitonin gene-related peptide (CGRP) receptor antagonist and the first branded medication available through Cove.
BJ Jones, Chief Commercial Officer of Migraine and Common Diseases commented, Biohaven is committed to providing people with migraine innovative options for accessing healthcare, particularly given the challenges facing patients in the current healthcare environment. During this period, patients may experience an increase in attacks and it is important to keep those suffering from migraine functioning normally, and out of doctor offices/emergency rooms to comply with travel restrictions. By making NURTEC ODT available through Cove's platform, we can provide migraine patients with another option to access doctors and treatment from the safety and comfort of their homes.
The U.S. Food and Drug Administration (FDA) approved NURTEC ODT for the acute treatment of migraine in adults on February 27, 2020. NURTEC ODT, which disperses almost instantly in a person's mouth without the need for water, works by blocking the CGRP receptor, treating a root cause of migraine. NURTEC ODT is not indicated for the preventive treatment of migraine.
Cove General Manager, Caroline Hofmann, added, There's no one size fits all solution for migraine sufferers. They deserve to have as many options as possible to find the right one for them. We're excited to be able to offer NURTEC ODT on Cove and make this innovative treatment more accessible than ever through our telemedicine platform, during this stressful time when migraine sufferers need it the most.
Alicia Torborg, Executive Director, Association of Migraine Disorders, said, Especially during this trying time, we all need to help patients get the care that they need when they need it. Telemedicine will help to fill this gap and may very well be the way of our future.
The collaboration with Cove is an expansion of existing tools to enhance access to NURTEC ODT for appropriate migraine patients. Existing offerings include a two-dose complementary sample pack available with a prescription from healthcare providers, a patient starter kit and a co-pay card where commercially insured patients can pay as little as $0 per month for NURTEC ODT. Patients using Cove will be eligible for the co-pay card.
More information about NURTEC ODT and available patient savings and access programs can be found at 1-833-4NURTEC and www.nurtec.com.
✔️ Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC ODT
💕 Found this article helpful? Spread the word and support us!